Fiasp 100 units/mL PumpCart solution for injection in cartridge *

  • Company:

    Novo Nordisk Limited
  • Status:

    No Recent Update
  • Legal Category:

    Product subject to medical prescription which may be renewed (B)
  • Active Ingredient(s):

    This medicinal product is subject to additional monitoring.

    *Additional information is available within the SPC or upon request to the company

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 03 September 2021

File name

Fiasp PumpCart_PIL_08-2021_clean_1630683610.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 2 - excipient warnings
  • Change to section 4 - possible side effects
  • Change to section 5 - how to store or dispose
  • Change to section 6 - what the product contains
  • Change to section 6 - date of revision
  • Removal of Black Inverted Triangle

Free text change information supplied by the pharmaceutical company

Black Triangle removed

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

 

Section 2, Warnings and precautions

Updates to the following bullet points:

  •  
  • Switching from other insulin medicinal products -- Your doctor may need to advise you on your insulin dose The insulin dose may need to be changed if you switch from another insulin.
  • If your insulin treatment is being combined with pioglitazone (oral antidiabetic medicine used to treat type 2 diabetes) - Tell your doctor as soon as possible if you get signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling caused by fluid retention (oedema).Pioglitazone used together with insulin - This may increase the risk of heart failure, see under ‘Other medicines and Fiasp’ below.
  • Eye disorder - Fast improvements in blood sugar control may lead to a temporary worsening of diabetic eye disorder such as diabetic retinopathy.
  •  
  •  
  • Ensuring you use the right type of insulin – always check the insulin label before each injection to avoid accidental mix-ups between insulin products.
  • Insulin treatment can cause the body to produce antibodies to insulin (substance that act against insulin). However, only very rarely, this will require a change to your insulin dose.

 

“Some conditions and activities can affect how much insulin you need. Talk to your doctor:

  • if you have trouble with your kidneys or liver, or with your adrenal, pituitary or thyroid glands.
  • if you exercise more than usual or if you want to change your usual diet, as this may affect your blood sugar level.
  • if you are ill, carry on taking your insulin and talk to your doctor.
  • if you are going abroad, travelling over time zones may affect your insulin needs and the timing of your injections.”

 

Fiasp PumpCart is only for use with the following insulin infusion pump systems: the Accu Chek Insight and YpsoPump insulin pumps. It must not be used with other pumps, as this may give you a wrong dose of your insulin and can lead to high or low blood sugar.”

 

Section 2, Other medicines and Fiasp

Text changes:

“Your blood sugar level may fall (hypoglycaemia) if you take:

•              other medicines for diabetes (oral and injectable)

•              sulphonamide antibiotics (for used to treat infections)

•              anabolic steroids (such as testosterone)

•              beta-blockers - for e.g.,(used to treat high blood pressure or angina)

They may make it harder to recognise the warning signs of low blood sugar (see section 4 ‘Warning signs of low blood sugar’)

•              acetylsalicylic acid (and other salicylates) -  f(or used to relieve pain and mild lower fever)

•              monoamine oxidase inhibitors (MAOI) inhibitors  - (for used to treat depression)

•              angiotensin converting enzyme (ACE) inhibitors (for some heart problems or high blood pressure)

 

Your blood sugar level may rise (hyperglycaemia) if you take:

•              danazol - (medicine acting on ovulation)for endometriosis

 

“Pioglitazone - oral antidiabetic medicine used to treat type 2 diabetes. Some patients with long-standing type 2 diabetes and heart disease or previous stroke who were treated with pioglitazone and insulin developed heart failure. Tell your doctor immediately if you have signs of heart failure such as unusual shortness of breath, rapid increase in weight or localised swelling (oedema).”

 

Section 2, Pregnancy and breast-feeding

“If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. This medicine can be used during pregnancy; however your insulin dose may need to be changed during pregnancy and after delivery. The amount of insulin you need usually falls during the first 3 months of pregnancy and increases for the remaining 6 months. Careful control of your diabetes is needed in pregnancy. Avoiding low blood sugar (hypoglycaemia) is particularly important for the health of your baby. After you have had your baby your insulin requirements will likely return to how much you needed before your pregnancy.

 

There are no restrictions on treatment with Fiasp during breast-feeding.”

 

Section 2 – Excipients

“This medicine contains less than 1 mmol sodium (23 mg) per dose,. This means that this medicine is to say essentially ‘sodium-free’.”

 

Section 4 – Possible side effects

“If you have a serious allergic reaction (including an anaphylactic shock) to insulin or any of the ingredients in Fiasp (how often this occurs is not known), stop using this medicine and contact emergency medical service straight away.”

 

“Skin changes at the injection site: If you inject insulin at the same place, the fatty tissue may shrink (lipoatrophy) or thicken (lipohypertrophy) (these are uncommon and may affect up to 1 in 100 people).”

 

High blood sugar (hyperglycaemia) frequency not known (cannot be estimated from the available data)

 

 

Section 5, How to store Fiasp

“After first opening or if carried as a spare:

•              Do not refrigerate during use.

•              You can keep your carry your cartridge (PumpCart) with you and keep it at room temperature (not above 30°C) for up to 2 weeks.”

 

Section 6

Each One pre-filled pen contains…”

 

Revision date updated to: 08/2021

 

Updated on 03 September 2021

File name

Fiasp SmPC-IE-ver8-Aug2021-clean_1630677115.pdf

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 9 - Date of first authorisation/renewal of the authorisation
  • Change to section 10 - Date of revision of the text
  • Removal of Black Inverted Triangle

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Black Triangle removed

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

 

Section 2

“Each One pre-filled pen contains…”

 

Section 4.2:

Renal and hepatic impairment

Renal or hepatic impairment may reduce the patient’s insulin requirements. In patients with renal or hepatic impairment, glucose monitoring should be intensified and the dose adjusted on an individual basis (see section 5.2).

 

Hepatic impairment

Hepatic impairment may reduce the patient’s insulin requirements. In patients with hepatic impairment, glucose monitoring should be intensified and the dose adjusted on an individual basis (see section 5.2).”

 

Text updates in “Method of administration”:

 

Fiasp 100 units/mL FlexTouch solution for injection in pre-filled pen

Administration with a pre-filled pen (FlexTouch)

The pre-filled pen (FlexTouch) is designed to be used with NovoFine Plus, NovoFine or NovoTwist injection needles. The pre-filled pen (FlexTouch) delivers 1–80 units in steps of 1 unit.

FlexTouch is colour-coded and accompanied by a package leaflet with detailed instructions for use to be followed. For instructions on administration, see “Instructions for Use” at the end of the package leaflet.

 

“Fiasp 100 units/mL Penfill solution for injection in cartridge

Administration with a reusable insulin pen

The cartridge (Penfill) is designed to be used with Novo Nordisk reusable insulin pens and NovoFine Plus, NovoFine or NovoTwist injection needles for subcutaneous injection only.

If administration by syringe or intravenous injection is necessary, a vial should be used. If administration by infusion pump is necessary, a vial or a PumpCart cartridge should be used (see section 6.6).”

 

“Fiasp 100 units/mL solution for injection in vial

Administration with a syringe

The vial is to be used with insulin syringes with the corresponding unit scale (unitsU-100 or 100 unitsU/mL).

 

Continuous subcutaneous insulin infusion (CSII)

Fiasp solution for injection in vial can be used for CSII in pumps suitable for insulin infusion and will cover both the bolus insulin requirement (approximately 50%) and basal insulin. It can be administered in accordance with the instructions provided by the pump manufacturer, preferably in the abdomen. Infusion site should be rotated within the same region to reduce the risk of lipodystrophy. When used with an insulin infusion pump, it should not be diluted or mixed with any other insulin medicinal products.”

 

Fiasp 100 units/mL PumpCart solution for injection in cartridge

Administration via Continuous Subcutaneous Insulin Infusion (CSII)

The cartridge (PumpCart) is only for use with an insulin infusion pump system designed to be used with this cartridge (see section 6.6), such as the Accu-Chek Insight and YpsoPump insulin pumps.

 

Intravenous use

Fiasp 100 units/mL solution for injection in vial

 

If necessary, Fiasp can be administered intravenously by health care professionals.

For intravenous use, it should be used at concentrations from 0.5 unit/mL to 1.0 unit/mL insulin aspart in infusion systems – using polypropylene infusion bags. Fiasp has been shown to be stable at room temperature for 24 hours in the infusion fluids such as sodium chloride 9 mg/mL (0.9%) solution or 5% glucose solution.

Fiasp must not be mixed with any other insulin or any other medicinal product except those mentioned in section 6.6. For instructions on dilution of the medicinal product before administration, see section 6.6.

Monitoring of blood glucose is necessary during insulin infusion. Care should be taken to ensure that the insulin is injected into the infusion bag and not simply the entry port.”

 

 

Section 4.4:

Hyperglycaemia and diabetic ketoacidosis

The use of inadequate doses or discontinuation of treatment, especially in patients requiring insulin, may lead to hyperglycaemia and diabetic ketoacidosis; conditions which are potentially lethal.”

 

“Fiasp 100 units/mL PumpCart solution for injection in cartridge

Misuse of PumpCart

The cartridge (PumpCart) is only for use with an insulin infusion pump system designed to be used with this cartridge, such as the Accu-Chek Insight and YpsoPump insulin pumps. It must not be used with other devices not designed for the cartridge, as this may result in incorrect insulin dosing and subsequent hyper- or hypoglycaemia (see section 6.6).”

 

“Combination of thiazolidinediones pioglitazone and insulin medicinal products

Cases of congestive heart failure have been reported when thiazolidinediones pioglitazone were used in combination with insulin, especially in patients with risk factors for development of congestive heart failure. This should be kept in mind if treatment with the combination of thiazolidinediones pioglitazone and insulin medicinal products is considered. If the combination is used, patients should be observed for signs and symptoms of congestive heart failure, weight gain and oedema. Thiazolidinediones Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs.”

 

“Excipients

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say i.e. essentially ‘sodium-free’.”

 

Section 4.6:

Breast-feeding

There are no restrictions on treatment with Fiasp during breast-feeding. Insulin treatment of the nursing breast-feeding mother presents no risk to the baby. However, the dosage may need to be adjusted.”

 

Section 5.1:

“Fiasp has an earlier onset of action compared to NovoRapid (see section 5.2), leading to a subsequent increased early glucose-lowering effect. This must be considered when prescribing Fiasp.”

 

Section 6.2:

“The medicinal product must not be diluted or mixed with any other medicinal products except infusion fluids as described in section 4.26.6.”

 

Section 6.3:

“Fiasp 100 units/mL PumpCart solution for injection in cartridge

 

After first opening or carried as a spare, the medicinal product may be stored for a maximum of 2 weeks below 30°C. Thereafter it can be used for up to 7 days below 37°C in an insulin infusion pump system designed to be used with this cartridge, such as the Accu-Chek Insight and YpsoPump insulin pumps (see section 6.6). Do not refrigerate. Do not freeze. If cartridge is carried as a spare and unused, the cartridge should be kept in the outer carton in order to protect from light.”

 

Section 6.4:

 

After first opening or carried as a spare For storage conditions after first opening of the medicinal product or carried as a spare, see section 6.3.”

 

Section 6.6:

Fiasp 100 units/mL FlexTouch solution for injection in pre-filled pen

The pre-filled pen (FlexTouch) is designed to be used with injection needles developed according to the pen needle ISO standard of a length between 4 mm to 8 mm and a gauge between 30G and 32G for subcutaneous injection only.

Needles and pre-filled pens must not be shared. The cartridge must not be refilled.

The patient should discard the needle after each injection.

 

Fiasp 100 units/mL Penfill solution for injection in cartridge

The cartridge (Penfill) is designed to be used with Novo Nordisk reusable insulin pens and injection needles developed according to the pen needle ISO standard of a length between 4 mm to 8 mm and a gauge between 30G and 32G for subcutaneous injection only.

Needles and cartridges must not be shared. The cartridge must not be refilled.

The patient should discard the needle after each injection.

 

Fiasp 100 units/mL solution for injection in vial

Needles and syringes must not be shared.

The patient should discard the needle after each injection.

 

Administration via CSII

When Fiasp is drawn from a vial, it can be used in an infusion pump (CSII) for a maximum of 6 days, as described in section 4.2 and in the package leaflet. Tubings in which the inner surface materials are made of polyethylene or polyolefin have been evaluated and found compatible with pump use.

 

Intravenous use

Fiasp has been shown to be stable at room temperature for 24 hours in the infusion fluids such as sodium chloride 9 mg/mL (0.9%) solution for injection or 5% glucose solution for injection.

For intravenous use, it should be used at concentrations from 0.5 unit/mL to 1 unit/mL insulin aspart in infusion systems – using polypropylene infusion bags.

 

Fiasp 100 units/mL PumpCart solution for injection in cartridge

The cartridge must not be shared or refilled.

 

The cartridge (PumpCart) is only for use with the followingan insulin infusion pump systems: designed to be used with this cartridge, such as the Accu-Chek Insight and YpsoPump insulin pumps. , as described in section 4.2. Tubings in which the inner surface materials are made of polyethylene or polyolefin have been evaluated and found compatible with pump use.”

 

Section 9:

“Date of latest renewal: 18 August 2021”

 

Section 10:

Revision date updated to: 08/2021

Updated on 03 October 2020

File name

Fiasp PumpCart_PIL_09-2020_clean_1601733304.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects

Free text change information supplied by the pharmaceutical company

Section 2 – what you need to know - warnings and precautions

New text:

Skin changes at the injection site

The injection site should be rotated to help prevent changes to the fatty tissue under the skin, such as skin thickening, skin shrinking or lumps under the skin. The insulin may not work very well if you inject into a lumpy, shrunken or thickened area (see section 3 How to use Fiasp®). Tell your doctor if you notice any skin changes at the injection site. Tell your doctor if you are currently injecting into these affected areas before you start injecting in a different area. Your doctor may tell you to check your blood sugar more closely, and to adjust your insulin or your other antidiabetic medications dose.

 

Section 4 – possible side effects

New text:

Skin changes at the injection site If you inject insulin at the same place, the fatty tissue may shrink (lipoatrophy) or thicken (lipohypertrophy) (may affect up to 1 in 100 people). Lumps under the skin may also be caused by build-up of a protein called amyloid (cutaneous amyloidosis; how often this occurs is not known). The insulin may not work very well if you inject into a lumpy, shrunken or thickened area. Change the injection site with each injection to help prevent these skin changes.

 

Deleted text:

Uncommon (may affect up to 1 in 100 people)

Changes under the skin where you use the injection (lipodystrophy): Fatty tissue under the skin may shrink (lipoatrophy) or get thicker (lipohypertrophy). Changing where you inject each time may reduce the risk of developing these skin changes. If you notice these skin changes, tell your doctor or nurse. If you keep injecting in the same place, these reactions can become more severe and affect the amount of medicine your body gets.

Updated on 03 October 2020

File name

Fiasp SmPC-IE-ver7-Sep2020-clean_1601724494.pdf

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.2 - method of administration

Updated text:

Fiasp is recommended to be administered subcutaneously by injection in the abdominal wall or the upper arm (see section 5.2). Injection sites should always be rotated within the same region in order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see sections 4.4 and 4.8).

 

Section 4.4

New text:

Skin and subcutaneous tissue disorders

Patients must be instructed to perform continuous rotation of the injection site to reduce the risk of developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin absorption and worsened glycaemic control following insulin injections at sites with these reactions. A sudden change in the injection site to an unaffected area has been reported to result in hypoglycaemia. Blood glucose monitoring is recommended after the change in the injection site from an affected to an unaffected area, and dose adjustment of antidiabetic medications may be considered.

 

Section 4.8

Addition to adverse reaction list, skin and subcutaneous tissue disorders:

Not known – cutaneous amyloidosis

† ADR from postmarketing sources.

 

Skin and subcutaneous tissue disorders

Lipodystrophy (including lipohypertrophy, lipoatrophy) and cutaneous amyloidosis may occur at the injection site and delay local insulin absorption. Lipodystrophy was reported at the injection/infusion site in patients treated with Fiasp (0.5% vs. 0.2% in comparator). Continuous rotation of the injection site within the particular given injection area may help to reduce or prevent the risk of developing these reactions (see section 4.4).

Updated on 01 October 2020

File name

2020-04 IE_Fiasp PumpCart PIL manuscript_launch_v4_clean_1601540492.pdf

Reasons for updating

  • New PIL for new product

Free text change information supplied by the pharmaceutical company

PIL upload for product launch

Updated on 01 October 2020

File name

Fiasp SmPC-IE-ver 6-Mar2020-clean_1601540420.pdf

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

SmPC upload for product launch